If passed, the TPP will lock in policies that will keep prices obscenely high.

– The TPP could tie policymakers’ hands by locking in the inability of our government to negotiate reasonable prescription prices in any future Medicare Part D reform.
– The TPP would prevent the reduction of extra-long monopolies for biologic medicines — some of which cost over $100,000 per year — and delay the timely development of affordable, life-saving biosimilars.
– The TPP would lock in perverse incentives that encourage pharmaceutical companies to “evergreen” profits, extending monopolies for making minor modifications to existing medicines rather than developing new medicines.
– In addition, efforts to reform our system and reduce medical costs in the future could be challenged outside our court system in unaccountable trade tribunals.